Prevalence of amyloidosis among patients with mild to severe aortic stenosis. Validation of screening parameters.

31 August 2024 (10:00 - 10:50)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Fabian Voss

University Hospital Duesseldorf, Duesseldorf (Germany)

8 More presentations in this session

Presentation thumbnail

Delays in diagnosis and treatment initiation of ATTR cardiac amyloidosis: a real-world data analysis

Doctor J. Vogel (Essen, DE)

Abstract Slides Video

Presentation thumbnail

Transthyretin stabiliser therapy in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis

Mr V. Ribeiro (Teresina, BR)

Abstract Slides Video

Presentation thumbnail

Prevalence of transthyretin amyloid cardiomyopathy in patients hospitalised for heart failure with preserved ejection fraction in an LATAM center.

Mr S. Decotto (Buenos Aires, AR)

Abstract Slides Video

Presentation thumbnail

Biomarkers for monitoring patients with cardiac amyloidosis during transthyretin-stabilizer therapy

Doctor J. Vogel (Essen, DE)

Abstract Slides

Presentation thumbnail

Relationship between changes in renal function after acute phase of tafamidis administration and left ventricular diastolic function at mid-term follow-up in transthyretin cardiac amyloidosis

Ms A. Senda (Kobe, JP)

Abstract Slides

Access the full session

Session thumbnail

Cardiac amyloidosis, sarcoidosis, and inflammation

The Event

Event poster

ESC Congress 2024

31 August 2024 10:00 CET

You may be interested in

Congress Session

Recent advances in clinical practice guidelines: what the imager needs to know and apply - Part 2

Congress Presentation

Heart failure

Congress Session

Imaging evaluation of heart failure with preserved ejection fraction: all you need to know!

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources